New England Biolabs
keyboard_backspaceBack to Home
Contact
5 rue Henri Auguste Desbruères
91000 Evry-Courcouronnes
France
Directeur Commercial NEB France
About us
"Created by scientists for scientists.”
NEB is recognized as a world leader in the research, development and production of enzymes for molecular biology. For 50 years, the company has been developing innovative, high-quality products to meet the needs of the biotherapy industry.
Business offer
NEB offers the widest range of enzymes for molecular biology and continues to expand its know-how in the fields of high-throughput sequencing (NGS), real-time PCR (RT)-qPCR, RNA analysis, genomic expression, synthetic biology, glycobiology and epigenetics.
Our reagents meet the highest quality standards (ISO 9001/13485, GMP-grade), and can be supplied in customized formats (flasks, concentration, lyophilization) to meet the requirements of biotherapy and bioproduction players, from their R&D and throughout their development.
Activities
- Service
- Research Unit
- Cardiology
- Genetic Diseases
- Oncology
- Nervous Central System
- Hematology
- Infectiology
- Immunology
- Ophthalmology
- Inflammation
- Other
- Target selection & validation
- Gene / protein discovery
- Expression and pathway analysis of target
- quantification of target
- Research exploratory companion biomarkers
- Hit discovery
- Screening & Identification
- Immunotherapy lead generation
- Gene modification / Transduction
- Retroviral & lentiviral vectors
- CRISPR/Cas9
- Immunotherapy lead optimization
- Engineering
- Preclinical biomarkers
- Research exploratory Companion biomarkers
- Predictive biomarkers
- Bioproduction
- Batches production type
- Yeast
- Bacterial
- Clinical biomarkers
- Predictive biomarkers
- Target Identification
- Gene / protein discovery
- Expression and pathway analysis of target
- quantification of target
- Research exploratory companion biomarkers
- Gene Cloning
- Gene augmentation
- Gene inhibition
- Killing Gene
- KI / KO
- (Gene) engineering
- CRISPR activation
- CRISPR interference
- TRAC gene editing
- Gene Delivery System
- Lentivirus
- Other Retrovirus
- Adeno-Associated Virus (AAV)
- Adenovirus (ADV)
- Biomarker Identification
- Research exploratory Companion biomarkers
- CAR Construction
- Engineering
- Antigen identification, selection, optimization, and validation
- Omics analysis
- Reverse vaccinology
- Epidemiology analysis
- Antigen expression systems
- Antigen characterization
- Antigen optimization:
- Generation of mutants
- Early purification
- Antigen selection: pathogen sequencing and functional antigens
- Surface glycoproteins
- Membrane antigens
- Pathogen-host knowledge
- Pathogen genetics and mechanism of action
- Biomolecular analysis
- Antigen-protective immune-response profile
- Humoral response characterization:
- Cell mediated immunity response
- Research exploratory biomarkers
- Vaccine: antigen format platforms
- Recombinant protein expression
- Bacterial
- Fungi
- Synthetic Peptides or oligomers
- Virus-like particles (VLP) and nanoparticle-based carriers
- Viral vector encoding target antigen
- DNA plasmid vaccine
- mRNA vaccine
- Other
- CMC
- Gene modification / Transduction
- Molecular biology
- Expression systems
- Formulation
- Formulation
- Lyophilization
- Bioproduction GMP
- Vaccine platform type
- Recombinant protein expression
- Synthetic Peptides or oligomers
- Virus-like particles (VLP) and nanoparticle-based carriers
- Viral vector encoding target antigen
- DNA plasmid vaccine
- mRNA vaccine
- Other
- Manufacturing Volume
- Small volume (< 100 L) adjusted to phase I/II needs: specify volume
- Large volume (100 – 1000 L) adapted for phase III needs
- Final scale up volume (> 1000 L) and validation for manufacturing
- Commercial supply during life cycle management
- Fill & finish
- Lyophilization
